New hope for kids with aggressive blood cancer: experimental therapy enters first human tests
NCT ID NCT07623681
First seen Jun 12, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called PA3-17 injection in 12 children and teens (ages 3-18) whose T-cell leukemia or lymphoma has returned or not responded to standard therapy. The main goal is to check safety and find the best dose. The treatment uses specially engineered immune cells to target and attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7+ T-ALL/LBL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PersonGen Anke Cellular Therapeutice Co,Ltd.
Hefei, Anhui, 230088, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.